-+ 0.00%
-+ 0.00%
-+ 0.00%

CULLINAN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR CLN-049, A NOVEL FLT3XCD3 T CELL ENGAGER, IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Reuters·12/01/2025 12:00:02

Please log in to view news